Rimonabant to Reduce Alcohol Consumption

Summary

Rimonabant to Reduce Alcohol Consumption is a clinical trial^[1].

Key Facts

• Rimonabant to Reduce Alcohol Consumption is in the country of United States^[2].
• Rimonabant to Reduce Alcohol Consumption's instance of is recorded as clinical trial^[3].
• Rimonabant to Reduce Alcohol Consumption's start time is recorded as +2003-12-31T00:00:00Z^[4].
• Rimonabant to Reduce Alcohol Consumption's end time is recorded as +2007-03-15T00:00:00Z^[5].
• Rimonabant to Reduce Alcohol Consumption's contributor to the creative work or subject is recorded as Sanofi^[6].
• Rimonabant to Reduce Alcohol Consumption's sponsor is recorded as National Institute on Alcohol Abuse and Alcoholism^[7].
• Rimonabant to Reduce Alcohol Consumption's main subject is recorded as Alcohol treatment outcome evaluation methodology: State of the art 1980–1984^[8].
• Rimonabant to Reduce Alcohol Consumption's number of participants is recorded as {'unit': '1', 'amount': '+54'}^[9].
• Rimonabant to Reduce Alcohol Consumption's title is recorded as Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week^[10].
• Rimonabant to Reduce Alcohol Consumption's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+21'}^[11].
• Rimonabant to Reduce Alcohol Consumption's ClinicalTrials.gov ID is recorded as NCT00075205^[12].
• Rimonabant to Reduce Alcohol Consumption's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+45'}^[13].
• Rimonabant to Reduce Alcohol Consumption's clinical trial phase is recorded as phase II clinical trial^[14].
• Rimonabant to Reduce Alcohol Consumption's research site is recorded as United States National Institutes of Health^[15].
• Rimonabant to Reduce Alcohol Consumption's study type is recorded as interventional study^[16].